Skip to main content

Advertisement

SpringerLink
Log in

Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)

  • Review
  • Published:
Familial Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schadendorf D, van Akkooi ACJ, Berking C et al (2018) Melanoma. Lancet (London, England) 392(10151):971–984. https://doi.org/10.1016/s0140-6736(18)31559-9

    Article  Google Scholar 

  2. Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer (Oxford, England: 1990) 41(1):45–60. https://doi.org/10.1016/j.ejca.2004.10.016

    Article  Google Scholar 

  3. Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263. https://doi.org/10.1016/j.cell.2012.06.024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer (Oxford, England: 1990) 41(14):2040–2059. https://doi.org/10.1016/j.ejca.2005.03.034

    Article  Google Scholar 

  5. Leachman SA, Carucci J, Kohlmann W et al (2009) Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61(4):677.e1–677.e14 https://doi.org/10.1016/j.jaad.2009.03.016

    Article  Google Scholar 

  6. Aoude LG, Wadt KA, Pritchard AL, Hayward NK (2015) Genetics of familial melanoma: 20 years after CDKN2A. Pigm Cell Melanoma Res 28(2):148–160. https://doi.org/10.1111/pcmr.12333

    Article  CAS  Google Scholar 

  7. Read J, Wadt KA, Hayward NK (2016) Melanoma genetics. J Med Genet 53(1):1–14. https://doi.org/10.1136/jmedgenet-2015-103150

    Article  CAS  PubMed  Google Scholar 

  8. Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264(5157):436–440

    Article  CAS  PubMed  Google Scholar 

  9. Zuo L, Weger J, Yang Q et al (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12(1):97–99. https://doi.org/10.1038/ng0196-97

    Article  CAS  PubMed  Google Scholar 

  10. Puntervoll HE, Yang XR, Vetti HH et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50(4):264–270 https://doi.org/10.1136/jmedgenet-2012-101455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Goldstein AM, Chan M, Harland M et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828. https://doi.org/10.1158/0008-5472.Can-06-0494

    Article  CAS  PubMed  Google Scholar 

  12. de Snoo FA, Bishop DT, Bergman W et al (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14(21):7151–7157. https://doi.org/10.1158/1078-0432.Ccr-08-0403

    Article  PubMed  Google Scholar 

  13. Potjer TP, Kranenburg HE, Bergman W et al (2015) Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant. Eur J Hum Genet EJHG 23(5):711–714. https://doi.org/10.1038/ejhg.2014.187

    Article  CAS  PubMed  Google Scholar 

  14. Wiesner T, Obenauf AC, Murali R et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018–1021. https://doi.org/10.1038/ng.910

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Aoude LG, Wadt K, Bojesen A et al (2013) A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS ONE 8(8):e72144. https://doi.org/10.1371/journal.pone.0072144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cheung M, Talarchek J, Schindeler K et al (2013) Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 206(5):206–210. https://doi.org/10.1016/j.cancergen.2013.05.018

    Article  CAS  PubMed  Google Scholar 

  17. Lin M, Zhang L, Hildebrandt MAT, Huang M, Wu X, Ye Y (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8(43):74936–74946. https://doi.org/10.18632/oncotarget.20465

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bishop DT, Demenais F, Iles MM et al (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41(8):920–925. https://doi.org/10.1038/ng.411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yokoyama S, Woods SL, Boyle GM et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99–103. https://doi.org/10.1038/nature10630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98. https://doi.org/10.1038/nature10539

    Article  CAS  PubMed  Google Scholar 

  21. Barrett JH, Iles MM, Harland M et al (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43(11):1108–1113. https://doi.org/10.1038/ng.959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46(5):478–481. https://doi.org/10.1038/ng.2947

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 107(2):408. https://doi.org/10.1093/jnci/dju408

    Article  Google Scholar 

  24. Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. https://doi.org/10.1126/science.1230062

    Article  CAS  PubMed  Google Scholar 

  25. Aoude LG, Heitzer E, Johansson P et al (2015) POLE mutations in families predisposed to cutaneous melanoma. Fam Cancer 14(4):621–628. https://doi.org/10.1007/s10689-015-9826-8

    Article  CAS  PubMed  Google Scholar 

  26. Teerlink CC, Huff C, Stevens J et al (2018) A nonsynonymous variant in the GOLM1 gene in cutaneous malignant melanoma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djy058

    Article  PubMed  PubMed Central  Google Scholar 

  27. Robles-Espinoza CD, Velasco-Herrera Mdel C, Hayward NK, Adams DJ (2015) Telomere-regulating genes and the telomere interactome in familial cancers. Mol Cancer Res MCR 13(2):211–222. https://doi.org/10.1158/1541-7786.Mcr-14-0305

    Article  CAS  PubMed  Google Scholar 

  28. de Lange T (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19(18):2100–2110. https://doi.org/10.1101/gad.1346005

    Article  CAS  Google Scholar 

  29. Donizy P, Kaczorowski M, Biecek P, Halon A, Szkudlarek T, Matkowski R (2016) Golgi-related proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in cutaneous melanoma: patterns of expression and prognostic significance. Int J Mol Sci 17(10):1619. https://doi.org/10.3390/ijms17101619

    Article  CAS  PubMed Central  Google Scholar 

  30. Law MH, Bishop DT, Lee JE et al (2015) Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet 47(9):987–995. https://doi.org/10.1038/ng.3373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337(6099):1190–1195. https://doi.org/10.1126/science.1222794

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Oldridge DA, Wood AC, Weichert-Leahey N et al (2015) Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 528(7582):418–421. https://doi.org/10.1038/nature15540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wright JB, Brown SJ, Cole MD (2010) Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 30(6):1411–1420. https://doi.org/10.1128/mcb.01384-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hua JT, Ahmed M, Guo H et al (2018) Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell 174(3):564–575. https://doi.org/10.1016/j.cell.2018.06.014

    Article  CAS  PubMed  Google Scholar 

  35. Vallarelli AF, Rachakonda PS, Andre J et al (2016) TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget 7(33):53127–53136. https://doi.org/10.18632/oncotarget.10634

    Article  PubMed  PubMed Central  Google Scholar 

  36. Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S (2012) Genetic counseling in melanoma. Dermatol Ther 25(5):397–402. https://doi.org/10.1111/j.1529-8019.2012.01499.x

    Article  PubMed  PubMed Central  Google Scholar 

  37. Swetter SM, Tsao H, Bichakjian CK et al (2018) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.08.055

    Article  PubMed  Google Scholar 

  38. Potjer TP, Bollen S, Grimbergen A et al (2018) Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Int J Cancer. https://doi.org/10.1002/ijc.31984

    Article  Google Scholar 

  39. Helgadottir H, Ghiorzo P, van Doorn R et al (2018) Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. J Med Genet. https://doi.org/10.1136/jmedgenet-2018-105610

    Article  PubMed  Google Scholar 

  40. Frebourg T (2014) The challenge for the next generation of medical geneticists. Hum Mutat 35(8):909–911. https://doi.org/10.1002/humu.22592

    Article  CAS  PubMed  Google Scholar 

  41. Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A (2017) Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 18(1):14. https://doi.org/10.1186/s12863-017-0479-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cust AE, Drummond M, Kanetsky PA et al (2018) Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies. J Invest Dermatol 138(12):2617–2624. https://doi.org/10.1016/j.jid.2018.05.023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gu F, Chen TH, Pfeiffer RM et al (2018) Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet 27(23):4145–4156. https://doi.org/10.1093/hmg/ddy282

    Article  CAS  PubMed  Google Scholar 

  44. Leachman SA, Lucero OM, Sampson JE et al (2017) Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36(1):77–90. https://doi.org/10.1007/s10555-017-9661-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

MV was supported by a grant from the Dutch Cancer Society (Grant No. UL2012-5489).

Author information

Authors and Affiliations

  1. Department of Dermatology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Mijke Visser & Nelleke Gruis

  2. Department of Clinical Genetics, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Nienke van der Stoep

Authors
  1. Mijke Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nienke van der Stoep
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nelleke Gruis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelleke Gruis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Visser, M., van der Stoep, N. & Gruis, N. Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018). Familial Cancer 18, 267–271 (2019). https://doi.org/10.1007/s10689-018-00115-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-018-00115-3

Search

Navigation